Cormedix (CRMD) has released an update.
CorMedix Inc. announced business updates and the expected launch of DefenCath on January 30, 2024, highlighting that it has received a benefit determination from the Center for Medicare & Medicaid Services. This information was detailed in a press release, which is included with the company’s recent Form 8-K filing.
For further insights into CRMD stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
